Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line 90Y-ibritumomab tiuxetan in advanced follicular lymphoma with rituximab consolidation for persistent molecular disease
2006-005778-34Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan and rituximab in follicular lymphoma (FL) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Clinical and molecular remission rate. Started Jan 2007; status: completed.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2006-005778-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005778-34.